WM46 is a metastatic human melanoma cell line that displays a pigmented fibroblastic morphology. This cell line was established from left chest & abdomen in a 43-year-old female patient with level IV superficial spreading melanoma and a tumor thickness of 1.44. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line expresses PTEN loss of function including hemizygous deletion, and R24C mutation at position 24 in the CDK4 gene. The R24C mutation results in an amino acid substitution at codon 24 in CDK4, from an arginine (R) to cysteine (C). This mutation abolishes the ability of CDK4 to bind to p16(INK4a). WM46 cells produce xenograft tumors when injected into immunocompromised mice.
Size
1 mL
Concentration
10.0 million cells/ml
Applications
The key applications of these cell lines include genetic studies, xenograft production, drug testing, and drug target discovery. These cell line models can be used in various biological assays, and for identifying critical target genes, and cell signaling pathways.
Other Names
Human Melanoma, patient derived tumor, tumor models, skin cancer, xenograft
Yongping Shao and Andrew E. Aplin, Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res. 2010 Aug 15; 70(16): 6670-6681. doi: 10.1158/0008-5472.CAN-09-4473